17.81
Precedente Chiudi:
$16.49
Aprire:
$17.68
Volume 24 ore:
138.01K
Relative Volume:
0.25
Capitalizzazione di mercato:
$1.07B
Reddito:
$1.23M
Utile/perdita netta:
$-214.90M
Rapporto P/E:
-4.3205
EPS:
-4.1222
Flusso di cassa netto:
$-151.25M
1 W Prestazione:
+9.94%
1M Prestazione:
+21.32%
6M Prestazione:
-18.34%
1 anno Prestazione:
-44.05%
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SYRE
Spyre Therapeutics Inc
|
17.81 | 995.23M | 1.23M | -214.90M | -151.25M | -4.1222 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-08 | Iniziato | Leerink Partners | Outperform |
2025-03-18 | Iniziato | Wolfe Research | Outperform |
2024-09-04 | Iniziato | Wedbush | Outperform |
2024-07-16 | Iniziato | Evercore ISI | Outperform |
2024-05-02 | Iniziato | Robert W. Baird | Outperform |
2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
2023-12-20 | Iniziato | BTIG Research | Buy |
2023-12-11 | Iniziato | Guggenheim | Buy |
2023-12-11 | Iniziato | Jefferies | Buy |
2020-05-04 | Iniziato | Piper Sandler | Overweight |
2019-03-21 | Iniziato | JP Morgan | Overweight |
2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
2018-04-24 | Iniziato | Evercore ISI | Outperform |
2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Spyre Therapeutics Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional
Is Spyre Therapeutics Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
What analysts say about Spyre Therapeutics Inc. stockTremendous growth potential - jammulinksnews.com
What drives Spyre Therapeutics Inc. stock priceFree High-Return Strategy Alerts - jammulinksnews.com
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $53.40 - Defense World
Why Spyre Therapeutics Inc. stock attracts strong analyst attentionMomentum Swing Watchlist - beatles.ru
How Spyre Therapeutics Inc. stock performs during market volatilityPredictable High Return Trades - Newser
What makes Spyre Therapeutics Inc. stock price move sharplyPotential Rocket List - Newser
Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation - Yahoo Finance
Spyre Therapeutics Announces Grants of Inducement Awards - TradingView
GAMMA Investing LLC Purchases New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Spyre Therapeutics (SYRE) - The Globe and Mail
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward (SYRE) - Seeking Alpha
Spyre reports results from early stage TL1A antibody trials (SYRE) - Seeking Alpha
Transcript : Spyre Therapeutics, Inc.Special Call - MarketScreener
Spyre Therapeutics Announces Positive Interim Phase 1 Results fo - GuruFocus
Spyre Therapeutics Says Anti-TL1A Antibodies Met Objectives in Interim Phase 1 Study - MarketScreener
Spyre Therapeutics Announces Positive Phase 1 Results - TipRanks
Spyre Therapeutics (SYRE) Advances Clinical Trials with Encouraging Interim Results | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts - PR Newswire
Spyre Therapeutics to Host Conference Call and Webcast to Report - GuruFocus
Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment - Stock Titan
Bank of America Corp DE Reduces Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
California State Teachers Retirement System Grows Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 22,540 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Expands Team with Strategic Stock Options Worth $773K to Three Key Hires - Stock Titan
Squarepoint Ops LLC Purchases 6,754 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Transcript : Spyre Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 08 - marketscreener.com
Guggenheim reiterates Buy rating on Spyre stock citing pipeline progress By Investing.com - Investing.com Canada
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):